The internal trade probe of Taiwanese vaccine authors finds broader issues
The internal trade probe of a Taiwanese creator of Covid-19 vaccines has raised broader concerns over the country’s financial oversight and has confused President Tsai-ing Wen’s administration.
The Shilin district Taipei court office told the Financial Times that Medigen Vaccine Biologics Corporation is investigating the company’s shares after falling more than 20 percent before announcing positive results for the phase 2 clinical trials of the vaccine in June. The prosecutor declined to give further details about the investigation.
Last month, Tsai gave a TV address in which he dismissed allegations of political opponents because his government had blocked vaccine imports to raise the price of Medigen shares.